(Q34458553)

2 August 2017

1 reference

title

Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions (English)

1 reference

2 August 2017

0 references

M Gex-Fabry

1

1 reference

2 August 2017

A E Balant-Gorgia

series ordinal

2

1 reference

2 August 2017

L P Balant

series ordinal

3

1 reference

2 August 2017

publication date

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

24

1 reference

2 August 2017

issue

13

1 reference

2 August 2017

page(s)

947-959

1 reference

Olanzapine Serum Concentrations in Psychiatric Patients Given Standard Doses: The Influence of Comedication

2 August 2017

cites work

1 reference

12 December 2020

Drug interactions with newer antidepressants: role of human cytochromes P450

1 reference

12 December 2020

The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method.

1 reference

12 December 2020

Fluvoxamine-tricyclic antidepressant interaction

1 reference

12 December 2020

Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations

1 reference

12 December 2020

Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling

1 reference

12 December 2020

Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables

1 reference

12 December 2020

Important drug-drug interactions in the elderly

1 reference

12 December 2020

Is there a role for therapeutic drug monitoring of new anticonvulsants?

1 reference

12 December 2020

Therapeutic drug monitoring in special populations

1 reference

12 December 2020

Effects of carbamazepine on plasma haloperidol levels

1 reference

12 December 2020

Automated data bases used for pharmacoepidemiology research

1 reference

12 December 2020

Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting

1 reference

12 December 2020

Dosing of antidepressants--the unknown art

1 reference

12 December 2020

Monitoring blood levels of selected drugs. Remember to factor in the many confounding variables

1 reference

12 December 2020

Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry

1 reference

12 December 2020

Cytochrome P450 and therapeutic drug monitoring with respect to clozapine

1 reference

12 December 2020

Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.

1 reference

12 December 2020

Therapeutic drug monitoring opportunities in cancer therapy

1 reference

12 December 2020

Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection

1 reference

12 December 2020

Setting standards of practice in therapeutic drug monitoring and clinical toxicology: a North American view

1 reference

12 December 2020

Population pharmacokinetics. Theory and clinical application

1 reference

12 December 2020

Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling.

1 reference

12 December 2020

Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study

1 reference

12 December 2020

Best practice in therapeutic drug monitoring

1 reference

12 December 2020

Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy.

1 reference

12 December 2020

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

12 December 2020

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

1 reference

12 December 2020

Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data

1 reference

12 December 2020

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

1 reference

12 December 2020

The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline.

1 reference

12 December 2020

Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application

1 reference

12 December 2020

Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors.

1 reference

12 December 2020

Improved therapeutic monitoring of drug interactions in epileptic children using carbamazepine polytherapy

1 reference

12 December 2020

Interaction of fluoxetine with tricyclic antidepressants

1 reference

12 December 2020

Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review

1 reference

12 December 2020

Improving the use of therapeutic drug monitoring

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response

1 reference

12 December 2020

Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics

1 reference

12 December 2020

An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly

1 reference

12 December 2020

Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients

1 reference

12 December 2020

The role of automated record linkage in the postmarketing surveillance of drug safety: a critique

1 reference

12 December 2020

Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data

1 reference

12 December 2020

Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia

1 reference

12 December 2020

Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals

1 reference

12 December 2020

Lamotrigine drug interactions in a TDM material

1 reference

12 December 2020

A medication database - a tool for detecting drug interactions in hospital

1 reference

12 December 2020

Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update.

1 reference

12 December 2020

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method

1 reference

12 December 2020

Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients

1 reference

12 December 2020

Methods for estimating the occurrence of polypharmacy by means of a prescription database

1 reference

12 December 2020

Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate

1 reference

12 December 2020

Therapeutic drug monitoring of psychotropic medications.

1 reference

12 December 2020

Carbamazepine coadministration with fluoxetine or fluvoxamine

1 reference

12 December 2020

Therapeutic drug monitoring in antituberculosis chemotherapy

1 reference

12 December 2020

Evaluation of population pharmacokinetics in therapeutic trials. IV. Application to postmarketing surveillance

1 reference

12 December 2020

Coadministration of fluvoxamine increases serum concentrations of haloperidol

1 reference

12 December 2020

The regulatory view on drug-drug interactions

1 reference

12 December 2020

Increased trimipramine plasma levels during fluvoxamine comedication

1 reference

12 December 2020

Software for population pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Therapeutic drug monitoring and drug-drug interactions: a pharmacoepidemiological perspective.

1 reference

12 December 2020

Population pharmacokinetics of caffeine in neonates and young infants

1 reference

12 December 2020

Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients

1 reference

12 December 2020

Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide

1 reference

12 December 2020

Lithium population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.

1 reference

12 December 2020

Population Pharmacokinetics/Dynamics*

1 reference

12 December 2020

Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients

1 reference

12 December 2020

Metabolic interaction between fluoxetine and clomipramine: a case report

1 reference

12 December 2020

Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service

1 reference

12 December 2020

Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data

1 reference

12 December 2020

Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human

1 reference

12 December 2020

Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype

1 reference

12 December 2020

Lack of pharmacokinetic interaction as an equivalence problem

1 reference

12 December 2020

Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients

1 reference

12 December 2020

Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication.

1 reference

12 December 2020

Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics

1 reference

12 December 2020

10.2165/00002018-200124130-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1042190449

0 references

1 reference